The Alliance for Regenerative Medicine Elects Geoff MacKay as Next Chair, Welcomes New Officers and Executive Committee

The Alliance for Regenerative Medicine Elects Geoff MacKay as Next Chair, Welcomes New Officers and Executive Committee

WASHINGTON, DC -- (Marketwire) -- 11/15/12 -- The Alliance for Regenerative Medicine (ARM), the international organization representing the regenerative medicine community, announces the election of Geoff MacKay, President and Chief Executive Officer (CEO) of Organogenesis Inc., as its next chair and Keith Murphy, Chairman and CEO of Organovo, as Vice-Chair. Ed Field, Chief Operating Officer (COO) of Cytomedix, and Martin McGlynn, President and CEO of StemCells, Inc. were elected to the two other officer positions. Mr. MacKay will replace Gil Van Bokkelen, Chairman and CEO of Athersys, who will complete his 2-year term as Chair on December 31, 2012.

"Thanks to the diligent efforts of our outgoing officers, ARM made significant progress advancing its proposed national strategy for regenerative medicine over the past two years, including a clearer understanding of the regulatory pathway and reimbursement, as well as greater clarity on product development standards," said Michael Werner, Executive Director of ARM. "Under their leadership, our membership has grown to include more than 120 companies and organizations. In addition, we have made progress with the FDA to clarify the development pathway for cell-based therapies, and dramatically increased bi-partisan support for the Regenerative Medicine Promotion Act."

"We are grateful for the many contributions Gil has made to ARM over the past couple years, and are pleased he will continue to serve as an ex-officio member of the Executive Committee," said Morrie Ruffin, Managing Director of ARM. "We are excited to build on our prior accomplishments, and are confident that Geoff and our other new officers will play a critical role in helping us realize the potential for regenerative medicine to revolutionize treating and curing many diseases."

"The Alliance serves as a catalyst in bringing together all of the stakeholders in the regenerative medicine world. It is an honor to be elected to chair ARM, the world's leading regenerative medicine trade organization," said Geoff MacKay, President and CEO of Organogenesis Inc. "During my term, we plan to continue working with the entire industry to ensure that innovative technologies make it to market, where they can reach and impact patients' lives."

Newly elected officers include: Chairman: Geoff MacKay, President and CEO of Organogenesis Inc.; Vice Chairman: Keith Murphy, Chairman and CEO of Organovo; Secretary: Marty McGlynn, President and CEO of StemCells, Inc.; Treasurer: Ed Field, COO of Cytomedix.

The elected members of the 2013 Executive Committee include:

Anthony Atala, Director and Professor, Wake Forest Institute for Regenerative Medicine
Chris Calhoun, Co-founder and CEO, Cytori Therapeutics
Leanna Caron, VP and General Manager, Cell Therapy and Regenerative
Medicine, Sanofi-Genzyme
Douglas Doerfler, President and CEO, MaxCyte
Silviu Itescu, Managing Director and CEO, Mesoblast
Edward Lanphier, President and CEO, Sangamo BioSciences
Robert Preti, Co-founder, President and CSO, Progenitor Cell Therapy
Amy Comstock-Rick, CEO, Parkinson's Action Network
Robert Shaw, Commercial Director, Stem Cell Initiative, EMD Millipore
Bernard Siegel, Executive Director, Genetics Policy Institute
Jay Siegel, Chief Biotechnology Officer, Johnson & Johnson
David Smith, Head, Cell Therapy, Lonza
Devyn Smith, COO, Neusentis Research Unit, Pfizer
Susan Solomon, Co-founder and CEO, New York Stem Cell Foundation
Matthias Steger, Global Head, Research and Technology Partnering, Roche Ltd.
Dean Tozer, Vice President, Corporate Development, Shire Regenerative Medicine
Alan Trounson, President, CIRM
Gil Van Bokkelen, Chairman and CEO, Athersys (ex-officio)
Matthew Vincent, Director, Business Development, Advanced Cell Technology
Claudia Zylberberg, President and CEO, Akron Biotech

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit

Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.